PMID- 27065861 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160412 LR - 20220409 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 7 DP - 2016 TI - The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis. PG - 70 LID - 10.3389/fphar.2016.00070 [doi] LID - 70 AB - BACKGROUND: Compound Kushen Injection (CKI) is a Chinese patent medicine approved by the China Food and Drug Administration for the treatment of various types of solid tumors. CKI, combined with transarterial chemoembolization (TACE), is believed to increase the therapeutic efficacy of unresectable hepatocellular carcinoma (HCC). We report an updated and extended meta-analysis with detailed outcomes of both the efficacy and adverse events (AEs) of CKI combined with TACE therapy. MATERIALS AND METHODS: Electronic databases, including PubMed, Embase, the Cochrane Library, the Chinese Biomedical Database (CBM), Wanfang, the VIP medicine information system (VMIS) and the China National Knowledge Infrastructure (CNKI), were examined for relevant articles before November 13, 2015. An odds ratio (OR) was used to estimate tumor response (TR), Karnofsky Performance Scale (KPS) improvement, Child-Pugh (CP) improvement, survival rate (SR) and AEs. A publication bias and a subgroup analysis were also assessed. RESULTS: Eighteen studies, with a total of 1,338 HCC patients who met the criteria for the meta-analysis, were included. TR, KPS improvement and CP improvement were significantly enhanced for the combination therapy compared to TACE alone (OR = 1.84, 95% CI: [1.46, 2.33], P < 0.00001; OR = 2.37, 95% CI: [1.76, 3.18], P < 0.00001; OR = 1.81, 95% CI: [1.08, 3.03], P = 0.02, respectively). The combination therapy was associated with an improvement in 1-year and 2-year SRs but not an improved 3-year SR (OR = 2.40; 95% CI: [1.59, 3.62], P < 0.0001; OR = 2.49, 95% CI: [1.24, 5.00], P = 0.01; OR = 2.49, 95% CI: [0.94, 6.61], P = 0.07, respectively). A safety analysis indicated that AEs (including nausea/vomiting, fever, hepatalgia, increased transaminase, increased bilirubin and leukopenia) were reduced for the combination treatment compared to TACE alone. CONCLUSION: The combination treatment of TACE and CKI was associated with improved TR, KPS and CP improvement and improved 1- and 2-year SRs in patients with unresectable HCC. The 3-year SR was not improved. The combination therapy resulted in a reduction in AEs. The findings of this study should be interpreted with caution because of the small sample size and study limitations. FAU - Ma, Xiao AU - Ma X AD - Department of Pharmacy, 302 Military Hospital of People's Liberation ArmyBeijing, China; Pharmacy College, Chengdu University of Traditional Chinese MedicineChengdu, China. FAU - Li, Rui-Sheng AU - Li RS AD - Research and Technology Service Center, 302 Military Hospital of People's Liberation Army Beijing, China. FAU - Wang, Jian AU - Wang J AD - Pharmacy College, Chengdu University of Traditional Chinese Medicine Chengdu, China. FAU - Huang, Yin-Qiu AU - Huang YQ AD - Department of Pharmacy, 302 Military Hospital of People's Liberation ArmyBeijing, China; Pharmacy College, Chengdu University of Traditional Chinese MedicineChengdu, China. FAU - Li, Peng-Yan AU - Li PY AD - China Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation Army Beijing, China. FAU - Wang, Ji AU - Wang J AD - Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University Chengdu, China. FAU - Su, Hai-Bin AU - Su HB AD - Liver Failure Treatment and Research Center, 302 Military Hospital of People's Liberation Army Beijing, China. FAU - Wang, Rui-Lin AU - Wang RL AD - Department of Integrative Medical Center, 302 Military Hospital of People's Liberation Army Beijing, China. FAU - Zhang, Ya-Ming AU - Zhang YM AD - China Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation Army Beijing, China. FAU - Liu, Hong-Hong AU - Liu HH AD - Department of Integrative Medical Center, 302 Military Hospital of People's Liberation Army Beijing, China. FAU - Zhang, Cong-En AU - Zhang CE AD - Pharmacy College, Chengdu University of Traditional Chinese MedicineChengdu, China; China Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation ArmyBeijing, China. FAU - Ma, Zhi-Jie AU - Ma ZJ AD - Beijing Friendship Hospital, Capital Medical University Beijing, China. FAU - Wang, Jia-Bo AU - Wang JB AD - China Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation Army Beijing, China. FAU - Zhao, Yan-Ling AU - Zhao YL AD - Department of Pharmacy, 302 Military Hospital of People's Liberation Army Beijing, China. FAU - Xiao, Xiao-He AU - Xiao XH AD - China Military Institute of Chinese Medicine, 302 Military Hospital of People's Liberation Army Beijing, China. LA - eng PT - Journal Article PT - Review DEP - 20160331 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC4814457 OTO - NOTNLM OT - Compound Kushen Injection OT - meta-analysis OT - systematic review OT - transarterial chemoembolization OT - unresectable hepatocellular carcinoma EDAT- 2016/04/12 06:00 MHDA- 2016/04/12 06:01 PMCR- 2016/03/31 CRDT- 2016/04/12 06:00 PHST- 2016/01/10 00:00 [received] PHST- 2016/03/09 00:00 [accepted] PHST- 2016/04/12 06:00 [entrez] PHST- 2016/04/12 06:00 [pubmed] PHST- 2016/04/12 06:01 [medline] PHST- 2016/03/31 00:00 [pmc-release] AID - 10.3389/fphar.2016.00070 [doi] PST - epublish SO - Front Pharmacol. 2016 Mar 31;7:70. doi: 10.3389/fphar.2016.00070. eCollection 2016.